{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-035960","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.997735+00:00","generated_at":"2026-05-31T05:17:57.123579+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cingulate starts final FDA-required study for lead ADHD asset CTx-1301; raises $10M+","bullets":["Commenced final FDA-required food effect study for CTx-1301 (dexmethylphenidate) for ADHD; data readout expected by end of 2024.","Raised over $10M in additional capital since mid-August 2024, including 58% from at-the-market facility.","Received notification from Nasdaq that company is now in compliance with listing requirements.","Reinstated CEO/COO/CFO base salaries to original levels ($503K, $424K, $350K) after late-2023 reductions.","Cost containment measures have saved approximately $1.45M cumulatively; headcount remains ~40% below 2023 levels."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-035960","json":"https://secwatch.observer/filing/0001493152-24-035960.json","markdown":"https://secwatch.observer/filing/0001493152-24-035960.md","text":"https://secwatch.observer/filing/0001493152-24-035960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224035960/0001493152-24-035960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224035960/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:17:57.123579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}